European Journal of Heart Failure·29 SepEffectiveness of Finerenone in Slowing Chronic Kidney Disease Progression After Hospitalization for Heart Failure: A FIDELITY Subgroup AnalysisRandomised trial in peopleFinerenonePaper
ESC Heart Failure·18 SepNeutrophil-to-Lymphocyte Ratio in Patients With Heart Failure: Findings From The EMPEROR ProgramTrial in peopleBiomarkersPaper
Journal of Cardiac Failure·21 AugInpatient Initiation of Target-Dose ACE Inhibitors and Lower Risk of Death or Kidney Failure in Veterans With HFrEF: Results From the National DCVA-HF RegistryStudy in peopleInterventionsPaper
ESC Heart Failure·18 AugDifferential Rates of Guideline-Directed Medical Therapy Modification in C-MIC and Control Patients: Results from the C-MIC II TrialTrial in peopleInterventionsPaper
European Heart Journal·18 AugFinerenone benefits in patients with cardio-kidney-metabolic syndrome with or without history of cancer: the FINE-HEART pooled analysisTrial in peopleInterventionsPaper
Journal of Cardiac Failure·11 AugThe HFpEF-ABA Score, Incident Heart Failure, and Finerenone in Chronic Kidney Disease with Type 2 DiabetesRandomised trial in 11,950 peopleFinerenonePaper
Journal of Cardiac Failure·8 AugImpact of Empagliflozin on Serum Calcium and Phosphate in Heart FailureRandomised trial in 9,718 peopleEmpagliflozinPaper
AHA Scientific Sessions 2025 Abstract·3 NovFinerenone Reduces Loop Diuretic Requirement in Patients with Type 2 Diabetes and CKD: Participant-Level Pooled Analysis of FIDELIO-DKD and FIGARO-DKDTrial in peopleInterventionsPaper
AHA Scientific Sessions 2025 Abstract·3 NovEffects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk: Insights from the FIDELITY ProgramTrial in peopleInterventionsPaper
AHA Scientific Sessions 2025 Abstract·3 NovEstimated Lifetime Benefits of Finerenone on Cardiorenal Morbidity and Mortality in Patients with Type 2 Diabetes and Chronic Kidney DiseaseTrial in peopleInterventionsPaper
AHA Scientific Sessions 2025 Abstract·3 NovTiming of Cardiovascular and Kidney Benefits with Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 DiabetesTrial in peopleInterventionsPaper
AHA Scientific Sessions 2025 Abstract·3 NovMajor Adverse Cardiovascular Events across the Spectrum of Cardio-Kidney-Metabolic Syndrome: A FINE-HEART Pooled AnalysisTrial in peopleInterventionsPaper
AHA Scientific Sessions 2025 Abstract·3 NovThe HFpEF-ABA Algorithm and Finerenone in Chronic Kidney Disease with Type 2 Diabetes: A FINE-HEART AnalysisTrial in peopleBiomarkersPaper
AHA Scientific Sessions 2025 Abstract·3 NovFinerenone Reduces Sudden Death across the Spectrum of Cardio-Kidney-Metabolism: the FINE-HEART Pooled AnalysisTrial in peopleInterventionsPaper